MedTrace Logo

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-01-07

No results posted yet for this study

Summary

The purpose of this study is to see if two treatments (extracorporeal photopheresis and Mesenchymal Stromal Cell (MSC) infusion, can be given safely together, and if they improve the symptoms of a Graft versus Host Disease (GvHD), a complication that can occur in people who undergo stem cell transplant.

Conditions

Interventions

BIOLOGICAL

Allogeneic mesenchymal stromal cells (MSCs)

Treatment dose 2 x10\^6 cells/kg (+/- 20%)

BIOLOGICAL

Extracorporeal photopheresis (ECP)

Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant

Sponsors & Collaborators

  • Molly Gallogly

    lead OTHER

Principal Investigators

  • Molly Gallogly, MD, PhD · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2024-12-01
Completion
2025-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05333029 on ClinicalTrials.gov